Cargando…

Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1

Advanced ovarian cancer usually spreads to the visceral adipose tissue of the omentum. However, the omental stromal cell-derived molecular determinants that modulate ovarian cancer growth have not been characterized. Here, using next-generation sequencing technology, we identify significantly higher...

Descripción completa

Detalles Bibliográficos
Autores principales: Au Yeung, Chi Lam, Co, Ngai-Na, Tsuruga, Tetsushi, Yeung, Tsz-Lun, Kwan, Suet-Ying, Leung, Cecilia S., Li, Yong, Lu, Edward S., Kwan, Kenny, Wong, Kwong-Kwok, Schmandt, Rosemarie, Lu, Karen H., Mok, Samuel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820618/
https://www.ncbi.nlm.nih.gov/pubmed/27021436
http://dx.doi.org/10.1038/ncomms11150
_version_ 1782425438682873856
author Au Yeung, Chi Lam
Co, Ngai-Na
Tsuruga, Tetsushi
Yeung, Tsz-Lun
Kwan, Suet-Ying
Leung, Cecilia S.
Li, Yong
Lu, Edward S.
Kwan, Kenny
Wong, Kwong-Kwok
Schmandt, Rosemarie
Lu, Karen H.
Mok, Samuel C.
author_facet Au Yeung, Chi Lam
Co, Ngai-Na
Tsuruga, Tetsushi
Yeung, Tsz-Lun
Kwan, Suet-Ying
Leung, Cecilia S.
Li, Yong
Lu, Edward S.
Kwan, Kenny
Wong, Kwong-Kwok
Schmandt, Rosemarie
Lu, Karen H.
Mok, Samuel C.
author_sort Au Yeung, Chi Lam
collection PubMed
description Advanced ovarian cancer usually spreads to the visceral adipose tissue of the omentum. However, the omental stromal cell-derived molecular determinants that modulate ovarian cancer growth have not been characterized. Here, using next-generation sequencing technology, we identify significantly higher levels of microRNA-21 (miR21) isomiRNAs in exosomes and tissue lysates isolated from cancer-associated adipocytes (CAAs) and fibroblasts (CAFs) than in those from ovarian cancer cells. Functional studies reveal that miR21 is transferred from CAAs or CAFs to the cancer cells, where it suppresses ovarian cancer apoptosis and confers chemoresistance by binding to its direct novel target, APAF1. These data suggest that the malignant phenotype of metastatic ovarian cancer cells can be altered by miR21 delivered by exosomes derived from neighbouring stromal cells in the omental tumour microenvironment, and that inhibiting the transfer of stromal-derived miR21 is an alternative modality in the treatment of metastatic and recurrent ovarian cancer.
format Online
Article
Text
id pubmed-4820618
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48206182016-04-17 Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1 Au Yeung, Chi Lam Co, Ngai-Na Tsuruga, Tetsushi Yeung, Tsz-Lun Kwan, Suet-Ying Leung, Cecilia S. Li, Yong Lu, Edward S. Kwan, Kenny Wong, Kwong-Kwok Schmandt, Rosemarie Lu, Karen H. Mok, Samuel C. Nat Commun Article Advanced ovarian cancer usually spreads to the visceral adipose tissue of the omentum. However, the omental stromal cell-derived molecular determinants that modulate ovarian cancer growth have not been characterized. Here, using next-generation sequencing technology, we identify significantly higher levels of microRNA-21 (miR21) isomiRNAs in exosomes and tissue lysates isolated from cancer-associated adipocytes (CAAs) and fibroblasts (CAFs) than in those from ovarian cancer cells. Functional studies reveal that miR21 is transferred from CAAs or CAFs to the cancer cells, where it suppresses ovarian cancer apoptosis and confers chemoresistance by binding to its direct novel target, APAF1. These data suggest that the malignant phenotype of metastatic ovarian cancer cells can be altered by miR21 delivered by exosomes derived from neighbouring stromal cells in the omental tumour microenvironment, and that inhibiting the transfer of stromal-derived miR21 is an alternative modality in the treatment of metastatic and recurrent ovarian cancer. Nature Publishing Group 2016-03-29 /pmc/articles/PMC4820618/ /pubmed/27021436 http://dx.doi.org/10.1038/ncomms11150 Text en Copyright © 2016, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Au Yeung, Chi Lam
Co, Ngai-Na
Tsuruga, Tetsushi
Yeung, Tsz-Lun
Kwan, Suet-Ying
Leung, Cecilia S.
Li, Yong
Lu, Edward S.
Kwan, Kenny
Wong, Kwong-Kwok
Schmandt, Rosemarie
Lu, Karen H.
Mok, Samuel C.
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
title Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
title_full Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
title_fullStr Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
title_full_unstemmed Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
title_short Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
title_sort exosomal transfer of stroma-derived mir21 confers paclitaxel resistance in ovarian cancer cells through targeting apaf1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820618/
https://www.ncbi.nlm.nih.gov/pubmed/27021436
http://dx.doi.org/10.1038/ncomms11150
work_keys_str_mv AT auyeungchilam exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT congaina exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT tsurugatetsushi exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT yeungtszlun exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT kwansuetying exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT leungcecilias exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT liyong exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT luedwards exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT kwankenny exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT wongkwongkwok exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT schmandtrosemarie exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT lukarenh exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1
AT moksamuelc exosomaltransferofstromaderivedmir21conferspaclitaxelresistanceinovariancancercellsthroughtargetingapaf1